He gave his first public speech to the ABPI annual conference on Thursday (26 April) in which he thanked his predecessor and discussed the future challenges for industry. He takes over from Simon Jose of GSK, and will serve for one year with the option of standing for re-election in a year’s time.
Commenting on his appointment, Deepak said:
“It is a real honour to be serving the UK pharmaceutical industry and I am excited to be starting my work as President and leading the ABPI for the year to come. I would like to thank Simon Jose for his tireless work and for the great strides he has made to help modernise the ABPI, which I hope to build on.
"In my time as President, I want to ensure that people understand the importance of our industry in developing innovative medicines and the impact these medicines can have on improving patient health and transforming people’s lives. I will also be focused on ensuring that we continue a constructive conversation with government about the next pricing scheme - one which provides a fair price for medicines, encourages and supports the advancement of science through pharmaceutical R&D in the UK and also ensures that patients benefit from faster uptake of these innovative medicines.''
Commenting on Deepak’s appointment, Stephen Whitehead, CEO of the ABPI, said:
“I am looking forward to working with Deepak to take not only the ABPI forward, but industry as a whole. I want to thank Simon Jose personally for his time as President – he was a powerful advocate for the pharmaceutical industry and he leaves behind a great legacy.
“We are entering a new era of working in partnership with the NHS and Deepak’s leadership in these early stages will be crucial as we imbed new ways of working that will further patient care in the UK. The pricing of medicines and the negotiations we are entering in to later this year will be crucial to the future success of our industry and I know that Deepak’ wealth of experience will be invaluable.”
Commenting on Deepak’s appointment, Simon Jose, ABPI past President, said:
“It has been a great honour to serve the ABPI’s members and I have thoroughly enjoyed my time as President, representing the industry I believe passionately in. Throughout my tenure as President, the ABPI has worked tirelessly to set the agenda on a variety of issues – from reputation and joint working to innovation and pricing; and I am proud to have played my part. There will be many new challenges in the months to come but I am confident Deepak has the experience and expertise to provide industry with strong leadership and I wish him all the very best in his new role.”
ABPI Press Office
Tel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7808 641810 or +44 (0) 7850 312064
Notes to Editors
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all branded medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.